Photo from archive.org
In two pancreatic cancer trials-the randomized phase III PRODIGE 24/CCTG PA.6 and PREOPANC-1 trials-researchers found that experimental drug regimens for patients with resectable adenocarcinomas increased overall survival or showed a… Click to show full abstract
In two pancreatic cancer trials-the randomized phase III PRODIGE 24/CCTG PA.6 and PREOPANC-1 trials-researchers found that experimental drug regimens for patients with resectable adenocarcinomas increased overall survival or showed a trend in that direction. The findings could prompt changes in clinical practice for these patients.
Keywords:
survival seen;
improved survival;
seen pancreatic;
pancreatic cancer;
cancer
Journal Title: Cancer discovery
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Cancer discovery
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!